Eric Joseph
Stock Analyst at JP Morgan
(1.77)
# 3,317
Out of 5,182 analysts
125
Total ratings
41.18%
Success rate
-1.89%
Average return
Main Sectors:
Stocks Rated by Eric Joseph
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RXRX Recursion Pharmaceuticals | Upgrades: Overweight | $10 → $11 | $3.43 | +221.17% | 3 | Dec 17, 2025 | |
| TGTX TG Therapeutics | Maintains: Overweight | $46 → $49 | $35.25 | +39.01% | 5 | Nov 3, 2025 | |
| BEAM Beam Therapeutics | Maintains: Overweight | $48 → $46 | $28.62 | +60.73% | 4 | Oct 9, 2025 | |
| RVMD Revolution Medicines | Maintains: Overweight | $70 → $71 | $145.98 | -51.36% | 7 | Sep 25, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $57 → $64 | - | - | 4 | Jun 3, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Neutral | $44 → $7 | $3.64 | +92.31% | 4 | May 28, 2025 | |
| PRME Prime Medicine | Downgrades: Neutral | n/a | $3.74 | - | 5 | May 20, 2025 | |
| NVAX Novavax | Maintains: Underweight | $9 → $7 | $8.04 | -12.94% | 8 | May 9, 2025 | |
| PTCT PTC Therapeutics | Maintains: Overweight | $75 → $67 | $69.22 | -3.21% | 10 | May 7, 2025 | |
| OPK OPKO Health | Initiates: Neutral | n/a | $1.18 | - | 4 | Apr 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.26 | - | 4 | Feb 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $30 | $16.43 | +82.59% | 7 | Jan 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $14 | $10.60 | +32.08% | 5 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | - | - | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $23 | - | - | 1 | Nov 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $13 → $17 | $7.20 | +136.11% | 2 | Oct 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $14.95 | +40.47% | 5 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $11 → $10 | - | - | 4 | Aug 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 → $15 | $1.73 | +767.05% | 1 | May 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6 | $2.83 | +111.98% | 4 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $11 | $19.41 | -43.31% | 2 | Oct 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $300 → $100 | - | - | 1 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $28 → $5 | $2.27 | +119.96% | 2 | Aug 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | - | - | 6 | Aug 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $10 → $11 | $52.95 | -79.23% | 6 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | - | - | 2 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $120 | - | - | 2 | Feb 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $750 → $300 | $6.31 | +4,653.00% | 2 | Jan 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $14.94 | - | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $24 → $9 | $1.43 | +531.58% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.43 | - | 4 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $42 | $2.90 | +1,348.28% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $11 → $13 | $3.95 | +228.86% | 2 | Jan 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $11 | $0.21 | +5,196.10% | 3 | Nov 14, 2018 |
Recursion Pharmaceuticals
Dec 17, 2025
Upgrades: Overweight
Price Target: $10 → $11
Current: $3.43
Upside: +221.17%
TG Therapeutics
Nov 3, 2025
Maintains: Overweight
Price Target: $46 → $49
Current: $35.25
Upside: +39.01%
Beam Therapeutics
Oct 9, 2025
Maintains: Overweight
Price Target: $48 → $46
Current: $28.62
Upside: +60.73%
Revolution Medicines
Sep 25, 2025
Maintains: Overweight
Price Target: $70 → $71
Current: $145.98
Upside: -51.36%
Kymera Therapeutics
Jun 3, 2025
Maintains: Overweight
Price Target: $57 → $64
Current: -
Upside: -
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Neutral
Price Target: $44 → $7
Current: $3.64
Upside: +92.31%
Prime Medicine
May 20, 2025
Downgrades: Neutral
Price Target: n/a
Current: $3.74
Upside: -
Novavax
May 9, 2025
Maintains: Underweight
Price Target: $9 → $7
Current: $8.04
Upside: -12.94%
PTC Therapeutics
May 7, 2025
Maintains: Overweight
Price Target: $75 → $67
Current: $69.22
Upside: -3.21%
OPKO Health
Apr 25, 2025
Initiates: Neutral
Price Target: n/a
Current: $1.18
Upside: -
Feb 10, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.26
Upside: -
Jan 29, 2025
Maintains: Overweight
Price Target: $31 → $30
Current: $16.43
Upside: +82.59%
Jan 9, 2025
Maintains: Neutral
Price Target: $10 → $14
Current: $10.60
Upside: +32.08%
Nov 19, 2024
Initiates: Overweight
Price Target: $38
Current: -
Upside: -
Nov 5, 2024
Initiates: Overweight
Price Target: $23
Current: -
Upside: -
Oct 17, 2024
Maintains: Overweight
Price Target: $13 → $17
Current: $7.20
Upside: +136.11%
Sep 10, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $14.95
Upside: +40.47%
Aug 6, 2024
Maintains: Underweight
Price Target: $11 → $10
Current: -
Upside: -
May 3, 2024
Maintains: Neutral
Price Target: $14 → $15
Current: $1.73
Upside: +767.05%
Jan 29, 2024
Upgrades: Neutral
Price Target: $6
Current: $2.83
Upside: +111.98%
Oct 19, 2023
Maintains: Overweight
Price Target: $31 → $11
Current: $19.41
Upside: -43.31%
Aug 28, 2023
Downgrades: Neutral
Price Target: $300 → $100
Current: -
Upside: -
Aug 28, 2023
Downgrades: Neutral
Price Target: $28 → $5
Current: $2.27
Upside: +119.96%
Aug 10, 2023
Downgrades: Underweight
Price Target: n/a
Current: -
Upside: -
Aug 9, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $52.95
Upside: -79.23%
Nov 29, 2022
Downgrades: Underweight
Price Target: n/a
Current: -
Upside: -
Feb 9, 2022
Upgrades: Neutral
Price Target: $120
Current: -
Upside: -
Jan 7, 2022
Downgrades: Neutral
Price Target: $750 → $300
Current: $6.31
Upside: +4,653.00%
Oct 8, 2021
Downgrades: Underweight
Price Target: n/a
Current: $14.94
Upside: -
Jan 29, 2021
Downgrades: Neutral
Price Target: $24 → $9
Current: $1.43
Upside: +531.58%
Jan 29, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.43
Upside: -
Feb 24, 2020
Initiates: Overweight
Price Target: $42
Current: $2.90
Upside: +1,348.28%
Jan 24, 2019
Upgrades: Neutral
Price Target: $11 → $13
Current: $3.95
Upside: +228.86%
Nov 14, 2018
Maintains: Neutral
Price Target: $35 → $11
Current: $0.21
Upside: +5,196.10%